Shares of Monopar Therapeutics MNPR, a clinical-stage biotech, skyrocketed 383.5% previously three months fueled by a licensing settlement with AstraZeneca AZN, which granted MNPR an unique worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate). ALXN-1840 is an investigational once-daily, oral medication, which is being developed for treating Wilson illness, a uncommon and progressive genetic illness.
AstraZeneca had earlier introduced {that a} pivotal section III examine evaluating the candidate for the above indication had met its main endpoint. Though AZN terminated the ALXN-1840 program in 2023, Monopar took up the candidate upon the request of the Wilson Illness Affiliation. AstraZeneca’s termination of the ALXN-1840 program was primarily based on the evaluate of outcomes from section II mechanistic research and discussions with regulatory authorities.
Prior to now six months, shares of Monopar have rallied 525.5% in opposition to the industry’s 4.8% decline.
Picture Supply: Zacks Funding Analysis
Extra on the Licensing Deal Between MNPR and AZN
The licensing settlement with AstraZeneca added a late-stage candidate to Monopar’s early-stage pipeline. This has introduced MNPR considerably near changing into a commercial-stage firm.
Following the deal, Monopar has assumed tasks for all future international growth and commercialization actions associated to ALXN-1840 to deal with Wilson illness. Administration believes that the corporate’s experience in uncommon illness drug growth and commercialization will catapult ALXN-1840 right into a profitable product for the above indication.
Beneath the phrases of the transaction, Monopar is liable to make an undisclosed upfront money fee to AstraZeneca, together with a stake in its fairness, in consideration of the worldwide rights to ALXN-1840. The corporate shall even be liable to make extra funds to AZN primarily based on the achievement of sure pre-determined regulatory and gross sales milestones. AstraZeneca can be eligible to obtain tiered royalties on internet gross sales from Monopar if ALXN-1840 is authorized and launched.
Per MNPR, ALXN-1840 has vital market alternative as one in 30,000 reside births in the US are affected by Wilson illness.
Monopar will initially be specializing in growing ALXN-1840 for sufferers with extra extreme Wilson illness signs. It’s gearing as much as maintain discussions with the FDA to determine a path ahead for the candidate.
Aside from ALXN-1840, the corporate is at the moment evaluating a number of different candidates for varied oncology indications in separate early-stage research.
Monopar Therapeutics Inc. Value and Consensus
Monopar Therapeutics Inc. price-consensus-chart | Monopar Therapeutics Inc. Quote
MNPR’s Zacks Rank & Different Shares to Think about
Monopar at the moment sports activities a Zacks Rank #1 (Sturdy Purchase).
Another top-ranked shares from the sector are Fortress Biosciences CSTL and Spero Therapeutics SPRO, every presently sporting a Zacks Rank #1. You’ll be able to see the complete list of today’s Zacks #1 Rank stocks here.
Prior to now 60 days, 2024 estimates for Fortress Biosciences have improved from a lack of 59 cents per share to earnings of 34 cents. Throughout the identical timeframe, loss per share estimates for 2025 have narrowed from $2.15 to $1.84. Prior to now three months, shares of Fortress Biosciences have misplaced 6.2%.
CSTL’s earnings beat estimates in every of the trailing 4 quarters, delivering a median shock of 172.72%.
Prior to now 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents throughout the identical timeframe. Prior to now three months, Spero’s shares have misplaced 20.2%.
SPRO’s earnings beat estimates in two of the trailing 4 quarters and missed the mark within the different two, delivering a median shock of 94.42%.
Simply Launched: Zacks High 10 Shares for 2024
Hurry – you’ll be able to nonetheless get in early on our 10 prime tickers for 2025. Handpicked by Zacks Director of Analysis Sheraz Mian, this portfolio has been stunningly and persistently profitable. From inception in 2012 by means of November, 2024, the Zacks High 10 Shares gained +2,112.6%, greater than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed by means of 4,400 corporations lined by the Zacks Rank and handpicked the very best 10 to purchase and maintain in 2025. You’ll be able to nonetheless be among the many first to see these just-released shares with monumental potential.
AstraZeneca PLC (AZN) : Free Stock Analysis Report
Spero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report
Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report
Monopar Therapeutics Inc. (MNPR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
